ABSTRACT
Objectives Clinical trials (CTs) are essential for improving patient care by evaluating new treatments’ safety and efficacy. A key component in CT protocols is the study population defined by the eligibility criteria. This study aims to evaluate the effectiveness of large language models (LLMs) in encoding eligibility criterion information to support CT protocol design.
Materials and Methods We extracted eligibility criterion sections, phases, conditions, and interventions from CT protocols available in the ClinicalTrials.gov registry. Eligibility sections were split into individual rules using a criterion tokenizer and embedded using LLMs. The obtained representations were clustered. The quality and relevance of the clusters for protocol design was evaluated through 3 experiments: intrinsic alignment with protocol information and human expert cluster coherence assessment, extrinsic evaluation through CT-level classification tasks, and eligibility section generation.
Results Sentence embeddings fine-tuned using biomedical corpora produce clusters with the highest alignment to CT-level information. Human expert evaluation confirms that clusters are well-structured and coherent. Despite the high information compression, clusters retain significant CT information, up to 97% of the classification performance obtained with raw embeddings. Finally, eligibility sections automatically generated using clusters achieve 95% of the ROUGE scores obtained with a generative LLM.
Conclusions We show that clusters derived from sentence-level LLM embeddings are effective in summarizing complex eligibility criterion data while retaining relevant CT protocol details. Clustering-based approaches provide a scalable enhancement in CT design that balances information compression with accuracy.
Competing Interest Statement
The authors declare the following competing financial interest(s): P.K., F.M., Q.H., and P.A. work for Risklick AG. All other authors declare no competing financial interest.
Funding Statement
This work was supported by the Swiss Innovation Agency Innosuisse under the project with funding number 101.466 IP-ICT "CTxAI: Quality by design of clinical studies using explainable AI".
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
ClinicalTrials.gov
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The source data for this study is publicly available from ClinicalTrials.gov. The processed dataset generated and analyzed during the current study will be made available upon manuscript acceptance.
